Alligator Bioscience AB Interim Report January-September 2017
Three important collaborations in place. Results in November from ADC-1013 clinical phase I study. Significant events, July-September • Apte ...
Alligator Bioscience Aptevo Therapeutics: Tumor antigen 5T4 associated with many forms of solid tumors identified as the second target for ALG.APV-527
ALG.APV-527 – A novel bispecific antibody candidate being developed by Alligator Bioscience and Aptevo Therapeutics. Engineered to Eng ...
Alligator Bioscience to present ADC-1013 intratumoral clinical phase I study results at SITC in November 2017
Lund, Sweden, September 21, 2017 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmac ...
Alligator Bioscience signs immunotherapy research collaboration agreement for 4-1BB
Research team to be led by Professor Ignacio Melero, Center for Applied Medical Research (CIMA) and Clínica Universidad de Navarra, Spain Lu ...
Alligator Bioscience AB (Nasdaq Stockholm; ATORX) Interim report January – June 2017
“We have advanced our project pipeline significantly during the second quarter. The immuno-oncology antibody ATOR-1017 moved into pre-clinic ...
Aptevo Therapeutics and Alligator Bioscience commence IND-enabling development activities for new bispecific immunotherapy candidate ALG.APV-527
Novel Bispecific Antibody Targeting Biological Pathway Implicated in Multiple Solid Tumor Indications Seattle, WA, and Lund, Sweden – August ...
Aptevo Therapeutics and Alligator Bioscience announce plans to co-develop novel bispecific antibody for tumor-directed immunotherapy
Strategic partnership will advance development of a novel bispecific immuno-oncology antibody targeting compelling biological pathway implic ...
Alligator advances 4-1BB immuno-oncology antibody ATOR-1017 to pre-clinical development
Lund, Sweden – Alligator Bioscience AB (Nasdaq Stockholm; ATORX), a biotechnology company developing antibody-based pharmaceuticals for canc ...
Alligator Bioscience presents promising immuno-oncology data at US conference; – Strong new preclinical findings for ADC-1013 and ATOR-1015
Lund, Sweden – Alligator Bioscience AB (Nasdaq Stockholm; ATORX) today presented new pre-clinical data on the CD40 agonistic immuno-oncology ...